Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Aufreinigung
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogen
This GPLD1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 679-709 amino acids from the C-terminal region of human GPLD1.
GPLD1
Reaktivität: Human
Wirt: Kaninchen
Polyclonal
FITC
Applikationshinweise
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
2 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
GPLD1
(Glycosylphosphatidylinositol Specific phospholipase D1 (GPLD1))
GPLD1 is expressed in numerous tissues and cells and specifically cleaves GPI-anchored proteins. Liver has the highest level of GPI-PLD expression and is the primary organ contributing to GPLD1 in the serum. GPLD1 is abundant in serum in which it associates with polipoproteins AI and AIV. Increased serum GPLD1 is associated with insulin resistance and elevated serum triglycerides. Many surface proteins are attached to eukaryotic cell membranes via glycosylphosphatidylinositol (GPI) anchors that are covalently bound to the C-terminus of the protein and cleavage of the GPI moiety by GPLD1, only enzyme known that cleavage GPI anchor, may represent a means of regulating attachment of these proteins to the cell surface, or alternatively, their release into the extracellular environment.